Whistleblowers Paid $439M From False Claims Act Lawsuits in 2012

The federal government reports that it has collected nearly $5 billion through whistleblower lawsuits in 2012, with about $439 million of the money recovered paid to whistleblowers who brought the claims forward. 

The Department of Justice (DOJ) itself took in about $3.3 billion in 2012, through settlements and fines imposed under the False Claims Act, which allows the government to pursue companies for fraudulent acquisition of federal funding.

Under the qui tam provisions of the act, whistleblowers who expose the fraud by revealing information not publicly accessible are entitled to a portion of the money recovered. Whistleblowers must be the first to bring the case to the government’s attention and not publicize the lawsuit until the Department of Justice decides whether to join the prosecution of the case.

Learn More About

Whistleblower Lawsuits

The largest whistleblower lawsuit settlement this year was against GlaxoSmithKilne, which paid $1.5 billion in False Claims Act fines for off-label marketing of drugs for uses that werenot approved by the FDA. That was part of a larger settlement over the company’s practices, which totaled about $3 billion.

The case stemmed from a whistleblower lawsuit filed by former Glaxo employees, who received a total of $131 million for bringing the case.

According allegations raised, GlaxoSmithKline illegally promoted their blockbuster antidepressant drug Paxil for treating depression in children from April 1998 to August 2003. However, the FDA had not approved it for use by anyone under the age of 18.

“In addition to the record-breaking amounts of money recovered for the taxpayers over the past four years, it is important that we not lose sight of the fact that the individual cases that are rolled up in these numbers have a real effect on individual people,” said Principal Deputy Assistant Attorney General Stuart Delery at a press briefing. “These cases involve a risk of harm to children and seniors, like in the cases against GlaxoSmithKline and other pharmaceutical companies that marketed their products for uses that were never approved by the FDA, undermining quality care and patient safety.”

Mortgage and housing fraud were also large contributors to this year’s total, which far exceeded last year’s take of about $3.2 billion total from False Claims Act settlements and fines.

Since January 2009, DOJ has collected a total of $13.3 billion through fraud charges for the federal government and whistleblowers.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.